Multicenter institutional experience of surgically resected thymic epithelial tumors (TETs)

An observational report on behalf of F.O.N.I.C.A.P. (Forza Operativa Nazionale Interdisciplinare Contro il Cancro del Polmone)

Giovenzio Genestreti, Luca Ampollini, Marco Angelo Burgio, Luigi Rolli, Stefano Sanna, Emanuela Scarpi, Manuela Monti, Luca Burgio Salvatore, Luciana Giannone, Antonio Santo, Maurizio Mezzetti, Claudia Casanova, Roberta Buosi, Michele Rusca, Dino Amadori, Giampaolo Gavelli

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: This multicenter analysis evaluated patient outcome and clinical pathologic features of thymic epithelial tumors after complete surgical resection and adjuvant treatment. Methods: Histologic classification and clinical staging were performed according to WHO classification and Masaoka staging system, respectively. Results: We analyzed 62 patients, 20 (32 %) of whom had myasthenia at diagnosis. Clinical and pathologic staging was as follows: 31 (50 %) and 30 (48 %) patients had stage I disease, 19 (30 %) and 22 (35 %) stage II, 5 (8 %) and 3 (6 %) stage III, 2 (4 %) and 2 (3 %) stage IVa, and 5 (8 %) and 5 (8 %) stage IVb, respectively. Histologic examination revealed 11 (19%) type A tumors, 19 (30%) type AB tumors, 7 (12 %) type B1 tumors, 11 (17 %) type B2 tumors, 11 (17 %) type B3 tumors, and 3 (5 %) type C tumors. Adjuvant therapies comprised chemotherapy in 3 (5 %) patients and radiotherapy in 16 (26 %) patients. Median follow-up was 71 months (range 1-145). DFS and OS at 48, 60, and 72 months were 89 and 89 %, 86 and 97 %, and 95% and 92%, respectively. Myasthenia at the onset of disease (P = 0.18 for DFS; P = 0.97) and tumor size >5 cm (P = 0.94 for DFS; P = 0.56) were not prognostic factors. Conclusions: TETs are rare and indolent tumors. Complete surgical resection followed by adjuvant therapies, such as chemotherapy and/or radiotherapy, in patients at risk of recurrence show very good DFS and OS results, even in cases with radically resected pleural-pulmonary metastases.

Original languageEnglish
Pages (from-to)2958-2963
Number of pages6
JournalAnnals of Surgical Oncology
Volume20
Issue number9
DOIs
Publication statusPublished - Sep 2013

Fingerprint

Neoplasms
Radiotherapy
Drug Therapy
Thymic epithelial tumor
Therapeutics
Neoplasm Metastasis
Recurrence
Lung

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Multicenter institutional experience of surgically resected thymic epithelial tumors (TETs) : An observational report on behalf of F.O.N.I.C.A.P. (Forza Operativa Nazionale Interdisciplinare Contro il Cancro del Polmone). / Genestreti, Giovenzio; Ampollini, Luca; Burgio, Marco Angelo; Rolli, Luigi; Sanna, Stefano; Scarpi, Emanuela; Monti, Manuela; Salvatore, Luca Burgio; Giannone, Luciana; Santo, Antonio; Mezzetti, Maurizio; Casanova, Claudia; Buosi, Roberta; Rusca, Michele; Amadori, Dino; Gavelli, Giampaolo.

In: Annals of Surgical Oncology, Vol. 20, No. 9, 09.2013, p. 2958-2963.

Research output: Contribution to journalArticle

Genestreti, Giovenzio ; Ampollini, Luca ; Burgio, Marco Angelo ; Rolli, Luigi ; Sanna, Stefano ; Scarpi, Emanuela ; Monti, Manuela ; Salvatore, Luca Burgio ; Giannone, Luciana ; Santo, Antonio ; Mezzetti, Maurizio ; Casanova, Claudia ; Buosi, Roberta ; Rusca, Michele ; Amadori, Dino ; Gavelli, Giampaolo. / Multicenter institutional experience of surgically resected thymic epithelial tumors (TETs) : An observational report on behalf of F.O.N.I.C.A.P. (Forza Operativa Nazionale Interdisciplinare Contro il Cancro del Polmone). In: Annals of Surgical Oncology. 2013 ; Vol. 20, No. 9. pp. 2958-2963.
@article{0c6d9f99940546d2907d21b22e2de93d,
title = "Multicenter institutional experience of surgically resected thymic epithelial tumors (TETs): An observational report on behalf of F.O.N.I.C.A.P. (Forza Operativa Nazionale Interdisciplinare Contro il Cancro del Polmone)",
abstract = "Background: This multicenter analysis evaluated patient outcome and clinical pathologic features of thymic epithelial tumors after complete surgical resection and adjuvant treatment. Methods: Histologic classification and clinical staging were performed according to WHO classification and Masaoka staging system, respectively. Results: We analyzed 62 patients, 20 (32 {\%}) of whom had myasthenia at diagnosis. Clinical and pathologic staging was as follows: 31 (50 {\%}) and 30 (48 {\%}) patients had stage I disease, 19 (30 {\%}) and 22 (35 {\%}) stage II, 5 (8 {\%}) and 3 (6 {\%}) stage III, 2 (4 {\%}) and 2 (3 {\%}) stage IVa, and 5 (8 {\%}) and 5 (8 {\%}) stage IVb, respectively. Histologic examination revealed 11 (19{\%}) type A tumors, 19 (30{\%}) type AB tumors, 7 (12 {\%}) type B1 tumors, 11 (17 {\%}) type B2 tumors, 11 (17 {\%}) type B3 tumors, and 3 (5 {\%}) type C tumors. Adjuvant therapies comprised chemotherapy in 3 (5 {\%}) patients and radiotherapy in 16 (26 {\%}) patients. Median follow-up was 71 months (range 1-145). DFS and OS at 48, 60, and 72 months were 89 and 89 {\%}, 86 and 97 {\%}, and 95{\%} and 92{\%}, respectively. Myasthenia at the onset of disease (P = 0.18 for DFS; P = 0.97) and tumor size >5 cm (P = 0.94 for DFS; P = 0.56) were not prognostic factors. Conclusions: TETs are rare and indolent tumors. Complete surgical resection followed by adjuvant therapies, such as chemotherapy and/or radiotherapy, in patients at risk of recurrence show very good DFS and OS results, even in cases with radically resected pleural-pulmonary metastases.",
author = "Giovenzio Genestreti and Luca Ampollini and Burgio, {Marco Angelo} and Luigi Rolli and Stefano Sanna and Emanuela Scarpi and Manuela Monti and Salvatore, {Luca Burgio} and Luciana Giannone and Antonio Santo and Maurizio Mezzetti and Claudia Casanova and Roberta Buosi and Michele Rusca and Dino Amadori and Giampaolo Gavelli",
year = "2013",
month = "9",
doi = "10.1245/s10434-013-3018-2",
language = "English",
volume = "20",
pages = "2958--2963",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York LLC",
number = "9",

}

TY - JOUR

T1 - Multicenter institutional experience of surgically resected thymic epithelial tumors (TETs)

T2 - An observational report on behalf of F.O.N.I.C.A.P. (Forza Operativa Nazionale Interdisciplinare Contro il Cancro del Polmone)

AU - Genestreti, Giovenzio

AU - Ampollini, Luca

AU - Burgio, Marco Angelo

AU - Rolli, Luigi

AU - Sanna, Stefano

AU - Scarpi, Emanuela

AU - Monti, Manuela

AU - Salvatore, Luca Burgio

AU - Giannone, Luciana

AU - Santo, Antonio

AU - Mezzetti, Maurizio

AU - Casanova, Claudia

AU - Buosi, Roberta

AU - Rusca, Michele

AU - Amadori, Dino

AU - Gavelli, Giampaolo

PY - 2013/9

Y1 - 2013/9

N2 - Background: This multicenter analysis evaluated patient outcome and clinical pathologic features of thymic epithelial tumors after complete surgical resection and adjuvant treatment. Methods: Histologic classification and clinical staging were performed according to WHO classification and Masaoka staging system, respectively. Results: We analyzed 62 patients, 20 (32 %) of whom had myasthenia at diagnosis. Clinical and pathologic staging was as follows: 31 (50 %) and 30 (48 %) patients had stage I disease, 19 (30 %) and 22 (35 %) stage II, 5 (8 %) and 3 (6 %) stage III, 2 (4 %) and 2 (3 %) stage IVa, and 5 (8 %) and 5 (8 %) stage IVb, respectively. Histologic examination revealed 11 (19%) type A tumors, 19 (30%) type AB tumors, 7 (12 %) type B1 tumors, 11 (17 %) type B2 tumors, 11 (17 %) type B3 tumors, and 3 (5 %) type C tumors. Adjuvant therapies comprised chemotherapy in 3 (5 %) patients and radiotherapy in 16 (26 %) patients. Median follow-up was 71 months (range 1-145). DFS and OS at 48, 60, and 72 months were 89 and 89 %, 86 and 97 %, and 95% and 92%, respectively. Myasthenia at the onset of disease (P = 0.18 for DFS; P = 0.97) and tumor size >5 cm (P = 0.94 for DFS; P = 0.56) were not prognostic factors. Conclusions: TETs are rare and indolent tumors. Complete surgical resection followed by adjuvant therapies, such as chemotherapy and/or radiotherapy, in patients at risk of recurrence show very good DFS and OS results, even in cases with radically resected pleural-pulmonary metastases.

AB - Background: This multicenter analysis evaluated patient outcome and clinical pathologic features of thymic epithelial tumors after complete surgical resection and adjuvant treatment. Methods: Histologic classification and clinical staging were performed according to WHO classification and Masaoka staging system, respectively. Results: We analyzed 62 patients, 20 (32 %) of whom had myasthenia at diagnosis. Clinical and pathologic staging was as follows: 31 (50 %) and 30 (48 %) patients had stage I disease, 19 (30 %) and 22 (35 %) stage II, 5 (8 %) and 3 (6 %) stage III, 2 (4 %) and 2 (3 %) stage IVa, and 5 (8 %) and 5 (8 %) stage IVb, respectively. Histologic examination revealed 11 (19%) type A tumors, 19 (30%) type AB tumors, 7 (12 %) type B1 tumors, 11 (17 %) type B2 tumors, 11 (17 %) type B3 tumors, and 3 (5 %) type C tumors. Adjuvant therapies comprised chemotherapy in 3 (5 %) patients and radiotherapy in 16 (26 %) patients. Median follow-up was 71 months (range 1-145). DFS and OS at 48, 60, and 72 months were 89 and 89 %, 86 and 97 %, and 95% and 92%, respectively. Myasthenia at the onset of disease (P = 0.18 for DFS; P = 0.97) and tumor size >5 cm (P = 0.94 for DFS; P = 0.56) were not prognostic factors. Conclusions: TETs are rare and indolent tumors. Complete surgical resection followed by adjuvant therapies, such as chemotherapy and/or radiotherapy, in patients at risk of recurrence show very good DFS and OS results, even in cases with radically resected pleural-pulmonary metastases.

UR - http://www.scopus.com/inward/record.url?scp=84881474363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881474363&partnerID=8YFLogxK

U2 - 10.1245/s10434-013-3018-2

DO - 10.1245/s10434-013-3018-2

M3 - Article

VL - 20

SP - 2958

EP - 2963

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 9

ER -